#ESMO22: Adaptimmune touts new PhI data for its cell therapy treatment
As the cell therapy biotech Adaptimmune has been eager to present data to progress with the FDA, the company hopes that its latest showing at ESMO will begin to impress regulators and investors.
On Friday, the UK biotech presented the newest Phase I SURPASS trial data for its MAGE-A4 cell therapy program.
The trial had 44 patients who received a single dose of the therapy with 43 able to be evaluated. Additionally, 25 patients had late-stage ovarian, urothelial and head and neck cancer. Here, the biotech saw 11 patients respond, good for a 44% objective response rate.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.